Go or no go? Lilly’s valuable diabetes contender
Tirzepatide heads for its first FDA approval and Enhertu eyes an earlier setting, as Verrica and Axsome keep their fingers crossed.
Go or no go? Bristol's first-in-class hopes
April should mark the approval of some of the biggest drugs of 2022, including Alnylam's vutrisiran, while TG will hope to be spared pain at the PI3K adcom.
Aclaris’s second crack at a topical Jak
But, with Incyte close to market and several big players moving forward, Aclaris’s project will need to stand out from the pack.
Roivant rewrites the Spac script, again
After revealing plans to buy one of its holdings out of a Spac, Roivant itself moves towards a blank-cheque company listing.